Zonisamide for neuropathic pain in adults

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 7, 2014, Pages

  Moore, R Andrew ^a   Wiffen, Philip J ^a   Derry, Sheena ^a   Lunn, Michael P T ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ZONISAMIDE;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; CANCER RELATED NEUROPATHY; CHRONIC PAIN; CLINICAL OUTCOME; COMPLEX REGIONAL PAIN SYNDROME TYPE I; COMPLEX REGIONAL PAIN SYNDROME TYPE II; DIABETIC NEUROPATHY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS NEUROPATHY; NEUROPATHIC PAIN; NEUROPATHY; OUTCOME ASSESSMENT; PAIN; PAINFUL DIABETIC NEUROPATHY; PHANTOM PAIN; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; POSTSTROKE PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; SPINAL CORD INJURY; SYSTEMATIC REVIEW; TRAUMATIC NEUROPATHIC PAIN; TREATMENT DURATION; TRIGEMINUS NEURALGIA;

EID: 85041740858     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011241     Document Type: Review

References (63)

1. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain 2011;152(3 Suppl):S49-64. [DOI: 10.1016/j.pain.2010.11.010].
2. Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Medicine 2005;6(3):225-34. [DOI: 10.1111/j.1526-4637.2005.05035.x].
3. Cochrane Pain, Palliative and Supportive Care Group. PaPaS Author and Referee Guidance. http://papas.cochrane.org/papas-documents (accessed 22 January 2013).
4. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurology 2010;9(8):807-19. [DOI: 10.1016/S1474-4422(10)70143-5].
5. Baron R, Wasner G, Binder A. Chronic pain: genes, plasticity, and phenotypes. Lancet Neurology 2012;11(1):19-21. [DOI: 10.1016/S1474-4422(11)70281-2].
6. Bektas N, Arslan R, Ozturk Y. Zonisamide: Antihyperalgesic efficacy, the role of serotonergic receptors on efficacy in a rat model for painful diabetic neuropathy. Life Sciences 2014;95(1):9-13. [DOI: 10.1016/j.lfs.2013.12.012].
7. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380-7. [DOI: 10.1016/j.pain.2007.08.013].
8. Brodie MJ, Ben-Menachem E, Chouette I, Giorgi L. Zonisamide: its pharmacology, efficacy and safety in clinical trials. Acta Neurologica Scandinavia 2012;126 (Suppl 194):19-28. [DOI: 10.1111/ane.12016].
9. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111].
10. Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3].
11. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al.Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005].
12. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. [DOI: 10.1093/ije/31.1.140].
13. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al.Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132-6. [DOI: 10.1111/j.1399-6576.2007.01486.x].
14. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice 2008;9:26. [DOI: 10.1186/1471-2296-9-26].
15. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12. [DOI: doi.org/10.1016/0197-2456(95)00134-4].
17. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al.A new definition of neuropathic pain. Pain 2011;152(10):2204-5. [DOI: 10.1016/j.pain.2011.06.017].
18. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339].
19. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology 1991;10(5-6):276-81.
20. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004846.pub2].
21. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Archives of Internal Medicine 1996;156(6):661-6.
22. Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1-3):122-7. [DOI: 10.1016/j.pain.2009.08.023].
23. Krusz JC. Treatment of chronic pain with zonisamide. Pain Practice 2003;3(4):317-20. [DOI: 10.1111/j.1530-7085.2003.03035.x].
24. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-33.
25. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3].
26. McQuay H, Moore R. An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998.
27. McQuay HJ, Smith LA, Moore RA. Chronic pain. In: Stevens A, Raftery J, Mant J, Simpson S editor(s). Health Care Needs Assessment. 3rd Edition. Oxford: Radcliffe Publishing, 2007. [ISBN: 978-1-84619-063-6].
28. Moisset X, Bouhassira D. Brain imaging of neuropathic pain. Neuroimaging 2007;37(Suppl 1):S80-8. [DOI: 10.1016/j.neuroimage.2007.03.054].
29. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7].
30. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5].
31. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2].
32. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al."Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [DOI: doi:10.1016/j.pain.2010.05.011].
33. Moore RA, Straube S, Derry S, McQuay HJ. Topical review: chronic low back pain analgesic studies - a methodological minefield. Pain 2010;149(3):431-4. [DOI: 10.1016/j.pain.2010.02.032].
34. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: doi:10.1136/ard.2009.107805].
35. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039].
36. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers-needed-to-treat analyses-do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain 2010;151(3):592-7. [DOI: doi:10.1016/j.pain.2010.07.013].
37. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2].
38. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9. [DOI: doi:10.1016/j.pain.2010.11.030].
39. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427-32. [DOI: 10.1097/EJA.0b013e328343c569].
40. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2].
41. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al.Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004].
42. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148].
43. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690].
44. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79-94. [DOI: 10.1111/papr.12050].
45. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions - individual patient data responder analysis. European Journal of Pain 2014;18(1):65-75. [DOI: 10.1002/j.1532-2149.2013.00341.x].
46. National Institute for Health and Care Excellence. Neuropathic pain - pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist settings. http://www.nice.org.uk/guidance/CG173 (accessed August 2013). [: www.nice.org.uk/nicemedia/live/13566/64189/64189.pdf].
47. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al.Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6-15. [DOI: 10.1111/j.1526-4637.2009.00685.x].
48. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. American Journal of Medicine 2009;122(10 Suppl):S22-32. [DOI: 10.1016/j.amjmed.2009.04.007].
49. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain 1994;56(2):127-38. [DOI: 10.1016/0304-3959(94)90086-8].
50. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
51. Sakaue A, Honda M, Tanabe M, Ono H. Antinociceptive effects of sodium channel-blocking agents on acute pain in mice. Journal of Pharmacological Sciences 2004;95(2):181-8.
52. Soni A, Batra R, Gwilym S, Spector T, Hart D, Arden N, et al.Neuropathic features of joint pain: a community-based study. Arthritis and Rheumatism 2013;65(7):1942-9. [DOI: 10.1002/art.37962].
53. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266-75. [DOI: 10.1111/j.1365-2125.2008.03200.x].
54. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia-responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [doi: 10.1186/1471-2474-11-150].
55. Takahashi Y, Hashimoto K, Tsuji S. Successful use of zonisamide for central poststroke pain. Journal of Pain 2004;5(3):192-4. [DOI: 10.1016/j.jpain.2004.01.002].
56. Tanabe M, Murakami T, Ono H. Zonisamide suppresses pain symptoms of formalin-induced inflammatory and streptozotocin-induced diabetic neuropathy. Journal of Pharmaceutical Sciences 2008;107(2):213-20.
57. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain 2006;7(4):281-9. [DOI: 10.1016/j.jpain.2005.11.008].
58. Tracey I. Can neuroimaging studies identify pain endophenotypes in humans?. Nature Reviews Neurology 2011;7(3):173-81. [doi: 10.1038/nrneurol.2011.4].
59. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al.Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630-5. [DOI: 10.1212/01.wnl.0000282763.29778.59].
60. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014;155(4):654-62. [DOI: 10.1016/j.pain.2013.11.013].
61. von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012;73(4):638-52. [DOI: 10.1016/j.neuron.2012.02.008].
62. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al.Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96. [DOI: 10.1016/S0140-6736(12)61729-2].
63. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al.Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2].